Close

Form 3 InMed Pharmaceuticals For: Nov 16 Filed by: Li Sarah

November 29, 2022 6:58 PM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Li Sarah

(Last) (First) (Middle)
C/O INMED PHARMACEUTICALS INC.
310-815 WEST HASTINGS ST.

(Street)
VANCOUVER A1 V6C1B4

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/16/2022
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, Accounting and Controller
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) 01/12/2022 01/25/2025 Common shares 242 151.9 (1) D  
Employee Stock Option (Right to Buy) 12/11/2021 12/15/2025 Common shares 80 70.89 (2) D  
Employee Stock Option (Right to Buy)   (3) 10/17/2026 Common shares 80 35 D  
Explanation of Responses:
1. Converted from Canadian exercise price of C$206.25 using an exchange rate of C$1.3578 = US$1.00
2. Converted from Canadian exercise price of C$96.25 using an exchange rate of C$1.3578 = US$1.00
3. 60 of the options have vested, 20 options will vest on Dec 16, 2022.
Remarks:
Exhibit List Exhibit 24 - Power of Attorney
/s/ Eric A. Adams, by power-of-attorney for Ms. Sarah Li 11/29/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

POWER OF ATTORNEY



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings